Display options
Cite
Yoshimura B, Hirota T, Takaki M, et al. Is quetiapine suitable for treatment of acute schizophrenia with catatonic stupor? A case series of 39 patients. Neuropsychiatr Dis Treat. 2013;9:1565-71doi: 10.2147/NDT.S52311.
Yoshimura, B., Hirota, T., Takaki, M., & Kishi, Y. (2013). Is quetiapine suitable for treatment of acute schizophrenia with catatonic stupor? A case series of 39 patients. Neuropsychiatric disease and treatment, 91565-71. https://doi.org/10.2147/NDT.S52311
Yoshimura, Bunta, et al. "Is quetiapine suitable for treatment of acute schizophrenia with catatonic stupor? A case series of 39 patients." Neuropsychiatric disease and treatment vol. 9 (2013): 1565-71. doi: https://doi.org/10.2147/NDT.S52311
Yoshimura B, Hirota T, Takaki M, Kishi Y. Is quetiapine suitable for treatment of acute schizophrenia with catatonic stupor? A case series of 39 patients. Neuropsychiatr Dis Treat. 2013;9:1565-71. doi: 10.2147/NDT.S52311. Epub 2013 Oct 10. PMID: 24143105; PMCID: PMC3797635.
Copy Download .nbib Format: NLM
Share it on

Neuropsychiatr Dis Treat. 2013;9:1565-71. doi: 10.2147/NDT.S52311. Epub 2013 Oct 10.

Is quetiapine suitable for treatment of acute schizophrenia with catatonic stupor? A case series of 39 patients.

Neuropsychiatric disease and treatment

Bunta Yoshimura, Tomoya Hirota, Manabu Takaki, Yoshiki Kishi

Affiliations

  1. Department of Psychiatry, Okayama Psychiatric Medical Center, Okayama, Japan ; Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.

PMID: 24143105 PMCID: PMC3797635 DOI: 10.2147/NDT.S52311

Abstract

PURPOSE: We aimed to determine which antipsychotic is most effective for the treatment of acute schizophrenia with catatonic stupor.

PATIENTS AND METHODS: Data were obtained from the medical records of 450 patients with the diagnosis of schizophrenia, who had received acute psychiatric inpatient treatment between January 2008 and December 2010 at our hospital. Among them, 39 patients (8.7%) met the definition of catatonic stupor during hospitalization. The diagnoses of schizophrenia in all 39 patients were reconfirmed during the maintenance phase. We retrospectively reviewed the medical records of these 39 patients to investigate which antipsychotics were chosen for treatment during the period from admission to recovery from catatonia, at the time of discharge, and 12 and 30 months after discharge.

RESULTS: As compared to other antipsychotics, it was found out that use of quetiapine had better outcomes and hence was used more often. A total of 61.5% of patients were on quetiapine at the time of recovery from catatonia and 51.3% of patients were on quetiapine at the time of discharge as compared to only 17.9% of patients on quetiapine on admission. However, at 12 and 30 months after discharge, the rates had decreased to 38.4% and 25.6%. Similarly, of 29 patients who were not administered electroconvulsive therapy, quetiapine was used at significantly higher rates at the time of recovery from catatonia (48.3%) than at the time of admission (17.2%). All 39 patients had received an antipsychotic as the first-line treatment and some antipsychotics might have contributed to the development of catatonia.

CONCLUSION: This study suggests that quetiapine is a promising agent for the treatment of schizophrenia with catatonic stupor during the acute phase.

Keywords: catatonia; electroconvulsive therapy; quetiapine; schizophrenia; stupor

References

  1. J Neuropsychiatry Clin Neurosci. 2011 Spring;23(2):223-6 - PubMed
  2. Ann Clin Psychiatry. 1994 Dec;6(4):259-66 - PubMed
  3. Anaesth Intensive Care. 1993 Aug;21(4):477-8 - PubMed
  4. Br J Psychiatry. 1992 Oct;161:558-60 - PubMed
  5. Eur Arch Psychiatry Clin Neurosci. 2001;251 Suppl 1:I8-13 - PubMed
  6. J Child Adolesc Psychopharmacol. 2007 Oct;17(5):733-5 - PubMed
  7. Schizophr Bull. 2010 Mar;36(2):239-42 - PubMed
  8. Acta Psychiatr Scand. 2012 Jan;125(1):33-8 - PubMed
  9. Clin Schizophr Relat Psychoses. 2010 Oct;4(3):185-8 - PubMed
  10. Acta Psychiatr Scand. 1994 Apr;89(4):285-8 - PubMed
  11. Psychiatry Clin Neurosci. 2006 Apr;60(2):256-8 - PubMed
  12. Psychosomatics. 2007 Nov-Dec;48(6):534-6 - PubMed
  13. J Clin Psychopharmacol. 1997 Jun;17(3):235-8 - PubMed
  14. Acta Psychiatr Scand. 1996 Feb;93(2):129-36 - PubMed
  15. Psychopharmacology (Berl). 1999 Mar;142(4):393-8 - PubMed
  16. Psychiatry Clin Neurosci. 2008 Aug;62(4):482 - PubMed
  17. Am J Psychiatry. 2003 Jul;160(7):1233-41 - PubMed
  18. Am J Psychiatry. 2001 Mar;158(3):360-9 - PubMed
  19. J Clin Psychopharmacol. 2010 Dec;30(6):745-6 - PubMed
  20. Eur Arch Psychiatry Clin Neurosci. 1999;249 Suppl 4:83-9 - PubMed
  21. J Clin Psychopharmacol. 1990 Feb;10(1):66-8 - PubMed
  22. Mov Disord. 1999 May;14(3):395-7 - PubMed
  23. Life Sci. 2000 Nov 24;68(1):29-39 - PubMed
  24. Compr Psychiatry. 2013 Nov;54(8):1210-4 - PubMed
  25. Int J Psychiatry Med. 1995;25(4):345-69 - PubMed
  26. Int J Neuropsychopharmacol. 2004 Mar;7(1):19-26 - PubMed
  27. CNS Drugs. 2013 Jul;27(7):515-29 - PubMed
  28. Clin Neuropharmacol. 2001 Jul-Aug;24(4):228-31 - PubMed
  29. J Nerv Ment Dis. 2011 Dec;199(12):987-8 - PubMed
  30. Acta Psychiatr Scand. 1996 Feb;93(2):137-43 - PubMed
  31. J Clin Psychopharmacol. 2009 Oct;29(5):497-9 - PubMed
  32. Acta Psychiatr Scand Suppl. 2013;(441):1-47 - PubMed
  33. Schizophr Bull. 2010 Mar;36(2):314-20 - PubMed
  34. Psychopharmacology (Berl). 2009 Oct;206(2):243-58 - PubMed

Publication Types